Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
BACKGROUND
Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine.


METHODS
In a randomized, double-blind trial conducted in 399 adults > or = 65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 microg, 45 microg, or 135 microg of each HA.


RESULTS
Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 microg or 135 microg of each HA.


CONCLUSIONS
Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults.
Infectious Disease Division, University of Rochester, Rochester, New York 14642, USA. john_treanor@urmc.rochester.edu
John J
JJ
Treanor
Gilbert M
GM
Schiff
Robert B
RB
Couch
Thomas R
TR
Cate
Rebecca C
RC
Brady
C Mhorag
CM
Hay
Mark
M
Wolff
Dewei
D
She
Manon M J
MM
Cox
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D016367:Baculoviridae / Q000235:genetics; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000235:genetics / Q000276:immunology
D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated; C510901:trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine